Department of Cardiac Surgery of Artois, Centre Hospitalier de Lens et Hôpital Privé de Bois Bernard, Ramsay, Santé, France.
Interact Cardiovasc Thorac Surg. 2022 Jul 9;35(2). doi: 10.1093/icvts/ivac182.
Our goal was to compare pacemaker rate usage following two different operating techniques for implanting the Perceval aortic valve replacement.
In this retrospective, single-centre study, we studied patients with isolated or concomitant Perceval aortic valve replacement operated on first between April 2013 and January 2016, following traditional operating techniques, with patients operated on between January 2016 and December 2020, after the adoption of a modified protocol based on different annulus sizing, higher positioning of the valve and no ballooning after valve deployment was adopted. The operations were performed by 2 surgeons, and patients were followed-up for a period of 30 days.
A total of 286 patients, with a mean age of 77 (4.9) years, had Perceval valves implanted during the study period, of which 79% were isolated aortic valve procedures. Most patients (66.8%) underwent minimally invasive procedures. Cross-clamp time was 55.1 (17.6) min. The overall postoperative pacemaker insertion rate was 8.4%, which decreased decisively after the 2016 change in the implant protocol (16% vs 5.6%; P = 0.005), adjusted odds ratio of 0.31 (95% confidence interval: 0.13-0.74, P = 0.012). Univariable and multivariable analysis showed that larger valve size (P = 0.01) and ballooning (P = 0.002) were associated with higher risk of implanting a pacemaker. Postoperative 30-day mortality was of 4.5%.
Improvement in the operating techniques for implanting the Perceval valve may decrease the rate of pacemakers implanted postoperatively. Although further studies are needed to confirm these results, such a risk reduction may lead to wider use of Perceval valves in the future, potentially benefiting patients who are suitable candidates for minimally invasive surgery.
我们旨在比较两种不同的经导管主动脉瓣置换术(TAVR)植入技术后起搏器的使用情况。
本回顾性单中心研究纳入了 2013 年 4 月至 2016 年 1 月期间采用传统技术植入经导管主动脉瓣置换术的患者(传统组),以及 2016 年 1 月至 2020 年 12 月期间采用改良技术植入 Perceval 主动脉瓣置换术的患者(改良组)。改良组基于不同的瓣环尺寸、更高的瓣膜位置和瓣膜部署后不球囊扩张来制定手术方案。该手术由 2 名外科医生完成,所有患者均随访 30 天。
研究期间共植入 286 例 Perceval 瓣膜,患者平均年龄为 77(4.9)岁,其中 79%为单纯主动脉瓣手术。大多数患者(66.8%)采用微创手术。体外循环时间为 55.1(17.6)min。术后总体起搏器植入率为 8.4%,在 2016 年植入方案改变后明显降低(16%比 5.6%;P=0.005),调整后比值比为 0.31(95%置信区间:0.13-0.74,P=0.012)。单变量和多变量分析表明,更大的瓣膜尺寸(P=0.01)和球囊扩张(P=0.002)与植入起搏器的风险增加相关。术后 30 天死亡率为 4.5%。
经导管主动脉瓣置换术植入技术的改进可能会降低术后起搏器的植入率。虽然还需要进一步的研究来证实这些结果,但这种风险的降低可能会导致未来更多地使用 Perceval 瓣膜,从而使适合微创手术的患者受益。